Unlike other forms of hepatocellular carcinoma (HCC), HCC induced by hepatitis B virus (HBV) infection shows a poor prognosis after conventional therapies. HBV induces liver cirrhosis and HCC. Many researchers have made efforts to find new substances that suppress the activity of HBV. Curcuma longa Linn (CLL) has been used for traditional medicine and food in Asia, especially in India, and has shown chemopreventive effects in a HBV-related in vitro model. This in vivo study was designed to seek the chemopreventive effects of CLL and its mechanisms. CLL mixture concentrated with dextrose water by boiling was lyophilized. CLL extracts were administrated to HBV X protein (HBx) transgenic mice aged 4 weeks for 2 to 4 weeks and aged 6 months for 3 months. After administration, histological changes in the liver tissue and expression of HBx-related genes were investigated. CLL-treated mice showed less visceral fat, a smaller liver/body weight ratio and delayed liver pathogenesis. Proliferating cell nuclear antigen (PCNA) expression was also increased in CLL-treated HBx transgenic mice, indicating regeneration of damaged liver tissue. CLL treatment decreased expression of HBx and increased p21 and cyclin D1 in livers of HBx transgenic mice. In addition, p-p53 was increased after CLL treatment. These results suggest that CLL can have beneficial effects on the early and late stages of liver pathogenesis, preventing and delaying liver carcinogenesis. This drug should be considered as a potential chemopreventive agent for HBV-related hepatocarcinogenesis.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality. More than 80% of HCC cases occur either in eastern Asia or in sub-Saharan Africa. 1 Major risk factors for the development of HCC are chronic infection with the hepatitis B virus (HBV) or hepatitis C virus (HCV), liver cirrhosis, exposure to aflatoxin B1, alcohol consumption, and diabetes. It has been estimated that 80% of HCC worldwide is etiologically associated with HBV. 2 Two billion people globally have been infected with HBV, 350 to 400 million are chronic carriers, and tens of millions of new cases occur annually. Of those infected, 15% to 40% develop HBV complications, namely cirrhosis or HCC. 3 Korea is one of the high-prevalence regions where at least 8% of the population is currently infected, so HCC induced by HBV infection has been considered not only a medical problem but also a social problem.
The partially double-stranded DNA genome of HBV contains 4 overlapping open-reading frames that encode the surface protein S, the core protein, a polymerase, and a multifunctional nonstructural protein called X. 4 Previous studies have shown that overexpression of the HBV large surface antigen (LHBS) and HBV X protein (HBx) leads to HCC development in transgenic mice. 5, 6 The induction of oxidative stress by these 2 viral proteins is supposed to contribute to the liver pathogenesis associated with HBV infection. 7 Curcuma longa Linn. (Zingiberaceae) (CLL) is the rhizome of turmeric. It has been used a common Indian dietary pigment and spice and has been reported to be a herbal medicine with several efficacies in a wide range of ailments, including wound healing, urinary tract infection, and liver ailments. 8, 9 In vitro and animal research has demonstrated anti-inflammatory, antioxidant, and antiproliferative properties of turmeric and its constituent curcumin. [10] [11] [12] [13] Based on these reports, researchers have made a study of cancer treatment. Multiple animal and in vitro studies report the antimutagenic properties of curcumin, including activity against colon, skin, and breast cancer cells. [14] [15] [16] [17] [18] [19] [20] There is also a report that curcumin inhibits the development of liver cirrhosis. 21 It is suggested that CLL extract suppressed the HBV replication and the transcription of HBV genes in HepG2.2.15 cells, which produce HBV particles, and elevated the transcription level of the endogenous antitumor p53 gene. 22 We hypothesized that CLL extracts could have a chemopreventive effect on liver pathology in animals. We administered CLL extracts orally to HBx transgenic mice in youth and old age using the same dose over 2 different periods. We checked their body weight regularly and sacrificed the mice after administration to observe their liver and fat phenotypes. We performed proliferating cell nuclear antigen (PCNA) staining, reverse transcription polymerase chain reaction (RT-PCR), quantitative RT-PCR (qRT-PCR), and Western blot to find the expression levels of genes and proteins related to proliferation.
Materials and Methods

Transgenic Animals
The production of HBx transgenic mice used in this study has been reported previously. 23 Briefly, HBx homozygous (+/+) transgenic mice were produced by mating HBx heterozygous transgenic mice with each other. To generate HBx homozygous transgenic mice on a mixed background of C57BL/6 and CBA strains, HBx homozygous C57BL/6 mice were crossed with CBA wild-type mice. The heterozygous transgenic offspring with a mixed background of C57BL/6 and CBA strains were then mated. Among their offspring, HBx homozygous transgenic mice were selected by genotyping. Then, selected mice were crossed up to F12, which is applicable for the study as an incipient inbred strain with a mixed genetic background of 2 strains (C57BL/6 and CBA). In the current study, F12 mice were used for in vivo analyses. HBx (+/+) transgenic mice have been verified by PCR analysis using primer sets. The primers used for PCR were as follows: one set is sense primer 5′-ttctcatctgccggtccgtg-3′ and antisense primer 5′-gggtcaatgtccatgcccca-3′ and another set is sense primer 5′-gaaaacacactcactgttcagag-3′ and antisense primer 5-gtaagccgctttctcttatgcag-3′. The wild-type mice are derived from littermates between HBx heterozygous transgenic male and female mice, with a mixed genetic background of 2 strains (C57BL/6 and CBA).
Mice were housed in a controlled pathogen-free environment. Mice were maintained in accordance with the guidelines of the Institutional Animal Care and Use Committee at the Korea Research Institute of Bioscience and Biotechnology (Daejeon, South Korea).
Preparation of CLL
CLL was obtained from the Daejeon Oriental Hospital (Daejeon, South Korea) and classified and identified by local experts. The extract of CLL was prepared by boiling. The dried prescription of CLL was boiled with distilled water for 3 hours. Total extract was centrifuged at 5000 rpm for 30 minutes and the supernatant of the extract was lyophilized and weighed. The lyophilized medicine was dissolved in distilled water to produce a concentration of 100 mg/mL.
CLL Administration
CLL was dissolved in autoclaved phosphate-buffered saline (PBS). Each mouse received either 50 mg/kg/d of CLL or PBS (as a control) through oral administration using a feeding needle. To study the therapeutic effects of the treatments on the early stage of liver pathogenesis, 4-week-old HBx transgenic male mice and their wild type male littermates were randomly assigned into different groups.
Mice were sacrificed at 2 weeks and 4 weeks after CLL administration. To study the therapeutic effects of the treatments on the precancerous stage of liver carcinogenesis, 6-month-old HBx transgenic male mice and their wild type male littermates were used. They received CLL (50 mg/kg/d) orally. Mice were sacrificed at 9 months old after CLL administration for 3 months. CLL (50 mg/kg/d) was given to 4-week-old HBx transgenic mice for 2 weeks (4 wk-2 wk), to 4-week-old HBx transgenic mice for 4 weeks, (4 wk-4 wk), and to 24-week-old mice for 12 weeks (6 mo-3 mo). Each study group had 9 to 11 mice.
Liver tissues were collected for pathologic and biochemical analysis.
Phenotype Analysis
We checked the body weight of the mice every week. We checked their liver and fat mass after administration. We evaluated if their body weight changed during this experiment and if the liver/body and fat/body ratio were different between treatment and control mice.
RT-PCR, qRT-PCR Analysis
Each sacrificed mouse's total RNA was converted into singlestrand cDNA. Total RNA was isolated from HBx mice liver tissue treated with PBS or CLL according to the manufacturers' specification using TRIzol reagent (Invitrogen, Korea). The concentrations of total RNA in the final elutes were determined by nano-drop. Total RNA was converted into single-strand cDNA using a cDNA-synthesis kit (Fermentas, Glen Burnie, MD). PCR was performed with the following primers HBx (5′-TTCTCATCTGCCGGTCC-GTG-3′: 5′-GGGTCAATGTCCATGCCCCA-3′), GAPDH (5′-ACCACAGTCCATGCCATCAC-3′: 5′-TCCACCAC CCTGTTGCTGTA-3′), p53 (5′-GTATCCGGGTGGAAG GAAAT-3′: 5′-TCTTCTGTACGGCGGTCTCT-3′), p21 (5′-GTCCAATCCTGGTGATGTCC-3′: 5′-GTTTTCGGC CCTGAGATGT-3′), PCNA (5′-TTGGAATCCCAGAACA GGAG-3′: 5′-CAGTGGAGTGGCTTTTGTGA-3′), cyclin D1 (5′-CACAGCGGTAGGGATGAAAT-3′: 5′-GGTAAT GCCATCATGGTTCC-3′), and actin (5′-AGCCATGTACG-TAGCCATCC-3′: 5′-CTCTCAGCTGTGGTGGTGAA-3′) to verify if equal amounts of RNA were used for reverse transcription and PCR amplification from different experimental conditions. Products were electrophoresed on a 1% agarose gel and visualized by staining with ethidium bromide. Amplification of the target genes by real-time RT-PCR was conducted using SYBR Green PCR premix Ex Taq (TAKARA, Madison, WI) followed by analysis using the Exicycler 96 Real-Time Quantitative Thermal block (Bioneer, Alameda, CA). Relative gene expression was calculated using the comparative Ct (2 -δ Ct) method.
Western Blot Analysis
Proteins (20 µg/sample) were separated on 12% sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes (Millipore, Bedford, MA). The membranes were primary blotted at 4°C overnight with primary antibody. The membranes were washed 5 times with 10 mM Tris-HCl (pH 7.5) plus 150 mM NaCl (Tris-buffered saline, TBS) that contained 0.2% Tween-20, and incubated with horseradish peroxidase conjugated IgG. After the removal of excess antibodies by washing with TTBS, specific binding was detected using a chemiluminescence detection system (Amersham, Berkshire, UK) according to the manufacturer's instructions. Rabbit polyclonal Abs to p21 and p53 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal Abs to p-p53 (ser15) and mouse monoclonal Abs to cyclin D1 were from Cell Signaling Technology (Beverly, MA), Rabbit polyclonal Abs to GAPDH were from LabFrontier (Seoul, Korea), and horseradish peroxidase conjugated goat Abs to mouse or rabbit IgG were from Amersham and Sigma (St Louis, MO).
Histopathological Diagnoses
The liver and fat weights were measured at mouse sacrifice. Liver samples were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin and PCNA according to standard methods.
Statistical Analysis
Statistical analyses were performed by unpaired or paired t tests as appropriate. All data are reported as means ± standard deviation (mean ± SD).
Results
HBx-Induced Liver Fat Accumulation and Enlargement Are Inhibited by CLL Administration
We treated HBx transgenic mice with CLL for 2 and 4 weeks at 1 month of age mice to study CLL's effect on the earlystage liver disease and for 3 months at 6 months old to study its effect on the late stage of liver damage. The animal protocol for CLL treatment is shown in Figure 1 . Body weights and blood glucose level were regularly checked during the CLL administration to determine toxicity and side effects of CLL. When sacrificing the mice, we measured liver and visceral fat weight in all experimental groups (4 wk-2 wk, 4 wk-4 wk, and 6 mo-3 mo). There were no significant differences in body weight or blood glucose level (data not shown) and no behavior changes were observed (data not shown). However, in the short-term groups (4 wk-2 wk, 4 wk-4 wk), mice showed loss of visceral fat and liver weight, especially the 4 wk-4 wk group (40% reduction in liver/body weight ratio and 26% in fat/body weight ratio; Figure 2 ).
Delayed Occurrence of Dysplasia and Hepatocellular Carcinoma by Treatment With CLL
Per os (p.o.) administration of CLL from 4 to 6 weeks, 4 to 8 weeks, and 6 to 9 months of age reduced liver damage and regressed the histopathology of the HBx transgenic mice. As shown in Table 1 , dysplasia was reduced to 40% in 6-week-old HBx mice treated with CLL for 2 weeks compared with 100% in the PBS control. CLL-treated 9-month-old HBx mice showed 40% less tumor formation compared with their PBS-treated counterparts. Interestingly, immune cell infiltration into hepatic tissues was higher in those treated with CLL. Thus, these results showed that CLL has therapeutic effects at both early and late stages of liver pathogenesis in HBx transgenic mice. Through hematoxylin and eosin staining, 6-week-old CLL-treated mice showed normal hepatocytes but the PBS-treated mice showed mildly dysplastic hepatocytes with relatively large and hyperchromatic nuclei ( Figures 3A  and 3B ). Eight-week-old mice hepatocytes had mild dysplasia in both groups, but CLL-treated mice showed few mitotic cells and infiltration of lymphocytes around the central vein ( Figures 3C and 3D) . The mice at 9 months, which are in late stage of hepatocarcinogenesis, showed moderate dysplasia of the hepatocytes with vesicular fatty changes in the nonneoplastic area in two groups, whereas CLL-treated mice only showed infiltration of lymphocytes around the central vein and dysplasia ( Figure 3E and 3F).
CLL Stimulated Hepatocyte Proliferation Leading to Damaged Cell Replacement in the HBx Transgenic Livers
To study whether cell proliferation and liver regeneration were affected by CLL, the PCNA staining was examined. Our data indicate that PCNA-positive cells were obviously increased after CLL administration in all groups (Figure 4 ).
CLL Reduced Expression of HBx and Increased Activity of p53
To investigate whether HBx gene expression is affected by CLL and whether this might contribute to the regression of liver pathology after CLL administration, the HBx mRNA expression levels were detected by RT-PCR and qRT-PCR. These data revealed that expression of the HBx gene was inhibited by CLL at both the early and cancerous stages in HBx transgenic mice (10% to 60% reduced after CLL treatment; Figure 5 ). We expected the mRNA level of the p53 to be increased, but p53 expression was not different even though p21, a p53 downstream target, was increased (a 1.4-to 4-fold increase after CLL treatment; Figure 5 ). We performed Western blot to check protein level and activity of p53. As with the mRNA data, total p53 level was not significantly different, but the p-p53 level was increased in CLL-treated mice especially in 4 wk-4 wk and 6 mo-3 mo groups ( Figure 6A ) and p21 was increased in precancerous stage CLL-treated mice ( Figure 6B ). These results suggest that CLL has little effect on total p53 level, but it does affect the activity of p53. The reactivated p53 increased the p21. 
Discussion
Curcuma longa Linn. (CLL) has been used as a traditional Asian medicine to treat gastrointestinal upset, arthritic pain, urinary tract infection, and liver ailments for a long time. 8 Although many researchers have been interested in CLL, they usually pay attention to the effect of its main constituent, curcumin. Curcumin, of course, is the main active substance of CLL. It is not easy to measure the effect of CLL because it is composed of many phytochemicals that do not exist equally in every batch or strain of CLL and this may induce diverse results when using the whole CLL. But CLL has been used as a spice for a very long time in India, south Asia, and Middle Eastern countries. This means that it is safe and stable in the human body when used as a food. It could also be supposed to have more a positive effect than curcumin, just one of its constituents. According to previous results, HBx transgenic mice show liver enlargement, accumulating visceral and liver fat. The causative agent among liver enlargement, fatty liver and liver dysfunction has been poorly investigated, but increasing evidence indicates that liver abnormality is related to liver cancer. [24] [25] [26] Previous in vitro study suggests CLL's effect on HBV replication and p53 expression. 22 We hypothesized CLL to have a chemopreventive effect on such liver pathology as cirrhosis and hepatocellular carcinoma induced by hepatitis B virus infection in animals. We administered CLL extracts in water solution p.o. to HBV X transgenic young and old mice using the same dose over different periods. HBV X protein transgenic mice usually have pathologic livers in old age because of the X protein activity. The HBx transgenic mice usually have many pathologic changes, including fatty change, inflammation, dysplasia, and tumorigenesis. The liver/body and fat/body ratios were decreased after CLL treatment. It is supposed that CLL might save the liver from malfunction caused by chronic pathologic change. Based on histopathological analysis, dysplasia was delayed and immune cells infiltrated the livers of the CLL-treated groups. Only 60% of CLL-treated mice had liver tumors. This is meaningful because all of the PBS-treated mice have HCC-affected livers. This could be evidence of the chemopreventive effect of CLL. PCNA is important for both DNA synthesis and DNA repair. 27, 28 In PCNA analysis, the number of PCNA-positive hepatocytes was increased in CLL-treated HBx mice compared with PBS-treated mice. These results suggested that the enhanced cell proliferation to liver regeneration induced by CLL helped replace damaged cells and repair DNA in the HBx transgenic mice; this may contribute in part to the chemopreventive effect of CLL on liver pathogenesis, not only on the early stage of liver disease but also in developed cancer.
In RT-PCR and qRT-PCR analysis, HBx expression was decreased regardless of the age of mice or administration period; p53 expression was not significantly different, but a downstream target of p53, p21, and cyclin D1 gene were increased in all of the three experimental conditions. Also, p53 activity was increased by CLL. It has been reported that the transcription of HBx gene is derived by HBV enhancer I and X promoter, which is controlled by the p53 protein, one of the most frequently mutated tumor suppressor genes in human cancers, which binds to a specific region within In Western blot analysis, p-p53, which is the active form of p-53, was detected more in CLL-treated mice. p21 and cyclin D1 expressions were increased in CLL-treated groups.
the HBV enhancer. 29 HBx could bind with the p53 protein within its transactivation domain in vivo and in vitro. The binding could prevent the p53 protein from entry into the nucleus and inhibit its function directly or indirectly [30] [31] [32] [33] [34] [35] and p53 induced degradation of HBx. 36 Inhibition of p53-mediated apoptosis by HBx might be in close connection with HBV-related hepatocellular carcinoma. In the results of this study, CLL downregulated HBx, reactivated p53, and increased its down stream genes, p21 and cyclin D1, regulating the aberrant cell cycle, and decreased HBx expression by accelerating its degradation.
Previous studies reported that p53 regulates respiratory and glycolytic pathways through its direct transcriptional targets 37 through activation of TIGAR (TP53-induced glycolysis and apoptosis regulator), a novel p53 target that regulates glycolysis and protects against oxidative stress. 38 One of the functions of CLL, loss of body weight especially visceral fat, is also explained by p53 activation. It is meaningful that these experiments reconstruct the results of previous in vitro experimental results in animals. These results suggest that CLL has a chemopreventive effect on liver pathology so that it could be used to prevent HCC in HBV-infected patients.
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